metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced - colorectal cancer (mCRC) 2
mCRC - (neo)adjuvant (NA)
mCRC - 1st line (L1) 5
mCRC - 2nd line (L2) 6
endometrial cancer 10

All treatments
chemotherapy
non platinum-based chemotherapy
nucleoside analogues (pyrimidine/purine)
capecitabine
Standard of Care (SoC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab
atezolizumab plus cometinib
atezolizumab plus FOLFOXIRI plus bevacizumab
atezolizumab plus SoC
avelumab based treatment
avelumab alone
durvalumab based treatment
nivolumab based treatment
nivolumab plus SoC
pembrolizumab based treatment
pembrolizumab alone
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab

versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs nucleoside analogues (pyrimidine/purine)
vs capecitabine
vs Standard of Care (SoC)
vs non active control
vs BSC
vs VEGF(R) inhibitor
vs bevacizumab based treatment
vs Bevacizumab plus FOLFOXIRI
vs placebo plus bevacizumab
vs regorafenib

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open